Lokomat® vs RoboGait® Under Different Guidance Force Settings in Motor-Incomplete SCI
Key facts
- Who runs it
- Ankara City Hospital Bilkent
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 19 people enrolled
- Started
- 23 Nov 2022
- Ended
- 23 Nov 2024
- Type of study
- Interventional, 3 groups
- Treatments tested
- Lokomat® V6 (GF < 90%)
- Lokomat® V6 (GF ≥ 90%)
- RoboGait®
- Record updated
- 22 August 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Adults aged 18 years or older
- Diagnosis of spinal cord injury (SCI) at T3 level or below
- Injury duration of no more than 2 years
- Functional classification of C or D based on the American Spinal Injury Association (ASIA) Impairment Scale
- ICD-10 diagnosis codes between S24.73-S24.77 or S34.70
Who cannot take part
- Joint disorders affecting mobility
- Cardiac problems or conditions impairing stabilization in the robotic systems
- Participation in another study
- Implanted electronic devices
- Orthostatic hypotension
- Severe spasticity in the lower extremities (Modified Ashworth Scale score ≥ 3)
- Presence of a colostomy
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study compares two robotic-assisted gait training systems, Lokomat® and RoboGait®, used under different guidance force (GF) settings, in people with motor-incomplete spinal cord injury (iSCI). Nineteen adults, aged 18 years or older, with injury at T3 level or below and classified as AIS C or D within two years of injury, participated. They were assigned to one of three groups based on the average GF used during training: Lok90- (GF < 90% with Lokomat®), Lok90+ (GF ≥ 90% with Lokomat®), and RG (GF ≥ 90% with RoboGait®). All participants completed 10 treadmill-based gait training sessions over 4 weeks, in addition to standard physiotherapy including stretching, strengthening, balance, and walking exercises. Walking ability, mobility, muscle strength, balance, independence in daily activities, and quality of life were assessed before and after the program. The study aimed to see whether the type of robot and GF setting affected recovery. Results showed modest improvements in some outcomes, with changes depending on the group and outcome measured. Findings suggest that adjusting GF settings may help tailor robotic gait training to individual needs.
The 3 groups in the trial
- Lok90- (GF < 90% with Lokomat®)Treatment being tested
Participants in this arm received robotic-assisted gait training using the Lokomat® V6 system (Hocoma AG, Switzerland) with an average guidance force (GF) of less than 90%. Training was conducted three times per week for 4 weeks, totaling 10 sessions. In addition to robotic gait training, participants also received conventional physiotherapy, including stretching, strengthening, balance, walking, and mobility exercises.
Treatment: Lokomat® V6 (GF < 90%)
- Lok90+ (GF ≥ 90% with Lokomat®)Treatment being tested
Participants in this arm received robotic-assisted gait training using the Lokomat® V6 system (Hocoma AG, Switzerland) with an average guidance force (GF) of 90% or higher. Training was conducted three times per week for 4 weeks, totaling 10 sessions. In addition to robotic gait training, participants also received conventional physiotherapy, including stretching, strengthening, balance, walking, and mobility exercises.
Treatment: Lokomat® V6 (GF ≥ 90%)
- RG (RoboGait®)Treatment being tested
Participants in this arm received robotic-assisted gait training using the RoboGait® system (BAMA Teknoloji, Türkiye) with an average guidance force (GF) of 90% or higher. Training was conducted three times per week for 4 weeks, totaling 10 sessions. In addition to robotic gait training, participants also received conventional physiotherapy, including stretching, strengthening, balance, walking, and mobility exercises.
Treatment: RoboGait®
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Lokomat® Versus RoboGait®: Comparative Effects on Walking, Mobility, and Quality of Life Under Different Guidance Force Settings in Motor-Incomplete Spinal Cord Injury
- Record updated
- 22 August 2025